atepeq/tico19 huggingface dataset:
In these protocols, identifiable personal data never leaves the device, and all matching happens on-device.
Ka'idawa anyi lan, sapsawi bayannabe ngəmbe asutinma so də təmma ro awo faidatəbe (misal ro waya) koljimba, kuru kalkaltə samma so kəla awo shima dəyen wakajin.
The Privacy Group at MIT Media Lab has been developing SafePaths, a platform for using privacy-preserving techniques when collecting and using location or path intersection data to track the spread of COVID-19.
Jami naptə kəlanzəbe "MIT Media Lab"be də awo shiro "SafePaths" sayin də tando sədin, adə shiye ngərwo nzunduwa ashirtəgə-liobe ro faidatin sa sapsawi bayanbe kəla na au zawal gurotəgə kəla tartəgə COVID-19ben baratin maa.
It is based on research from the whitepaper "Apps Gone Rogue: Maintaining Personal Privacy in an Epidemic" released in March 2020.Another similar effort is the SafeTrace platform by Enigma MPC, a company developing privacy technologies that was also originally founded at the MIT Media Lab.
Adəye kulashi 'whitepaper'be shiro "Apps Gone Rogue: Maintaining Personal Privacy in an Epidemic" sayin do kənagə Marchbe saa 2020 lan tutuluwuna də ro tənga'atəgə. Ngənəwu gade adəga samun də shi ma "SafeTrace platform by Enigma MPC" , kamfani do nzunduwa ashirtəgəbe sətandin ma do buro salakyen "MIT Media Lab" sha koksəna ma də.
SafeTrace utilizes secure hardware technologies to allow users to share sensitive location and health data with other users and officials, without compromising the privacy of that data.
"SafeTrace" də nzunduwa 'hardware'be nzəliwo'a faidatin faidatəwu'a kolzə sapsawi bayanbe ashirre kəla na be-a nəlewabe-a am faidatəwu gade so-a ndi katenzan faidatayin, ashirtəgə sapsawi bayanbe də bannazayimba ro.
On 5 April 2020, the global TCN Coalition was founded by groups that had coalesced around what was essentially the same approach and largely overlapping protocols, with the goal to reduce fragmentation, and enable global interoperability of tracing and alerting apps, a key aspect of achieving widespread adoption.
Kəntagə Aprilbe kaunzə 5 saa 2020, "the global TCN Coalition" də jamiwa kəlanza kəlzanaye kokkada, awo nganzazana shima nəm gadetə fulutə-akuru duya samma son cidatə appwa kam baratəbe hangal gərtəgəbe-aye, lamar kura fal gota tarrataa fandobe.
On 9 April 2020, the Singaporean government announced that it had open-sourced the BlueTrace protocol used by its official government app.
Kəntagə Aprilbe kaunzə 9 saa 2020 lan, gumnati Singaporebe awo shiro "the BlueTrace protocol" sayin do "official government app" nzəye faidatin ma də ndu soye raksə sowandin ro sədəna sə warmajio.
On 10 April 2020, Google and Apple, the companies that control the Android and iOS mobile platforms, announced an initiative for contact tracing, which they claimed would preserve privacy, based on a combination of Bluetooth Low Energy technology and privacy-preserving cryptography.
Kəntagə Aprilbe kaunzə 10 saa 2020be lan, Google-a Apple-a, kamfaniwa do ngərwowa Androidbe-a iOSbe-a sonotin də, cida amma manəm fandobe baditə warma'ada, shi doni gultəzan ashirtə səliwin, "Bluetooth Low Energy technology"-a "privacy-preserving cryptography" kəltə men.
They also published specifications of the core technologies used in the system.
Sandiye kuru ka'idawa nzunduwa zamanbe gədima suro nzundu au fasal dəyen faidatin ma də baksana.
According to Apple and Google, the system is intended to be rolled out in three stages:
Gultə Apple-a Google-a yen, fasal shima də katappa yakkə lan zunəm tulo nyiyatə:
rollout of tools to enable governments to create official privacy-preserving coronavirus tracing apps
karewa cidabe tulo do gomnati'a banazə manhaj koronabairos baranəm fandobe do ashirtə-siliwin sətandin.
integration of this functionality directly into iOS and AndroidGoogle and Apple plan to address the take-up and persistent surveillance problems by first distributing the system through operating system updates, and later removing it in the same way once the threat has passed.
Raktə cida adə diobe də iOS-a Android-a ro ikko: Google-a Apple-aye dawari sadin kazəyi citəbe-a lamarra ro shim ikkobe-a ro katap gotəgəro buro salakyen fasal də "operating system updates" men samtə men, kuru dare futu buron təkkəna yedei lan tulo sa kuwa də ba ro waljiya.
b'COVID-19 drug development is the research process to develop a preventative vaccine or therapeutic prescription drug that would alleviate the severity of 2019-20 coronavirus disease (COVID-19).
"b'COVID-19 drug development" də shima duluwu kulashibe kalimi kaltəgəbe au kurun do nəm zau kwasa koronabairosbe saa 2019-20 (COVID-19) də kəske ro sədin tandobe.
The International Clinical Trials Registry Platform of the WHO recorded 536 clinical studies to develop post-infection therapies for COVID-19 infections, with numerous established antiviral compounds for treating other infections under clinical research to be repurposed.
Ngərwowa Jarabtəwa Litaribe Bafro Ikkobe shiro "The International Clinical Trials Registry Platform" sayin WHOye dəye kəra litaribe sandi 536 kurunna ngawo kwasabe kamma sətanabe kwasa COVID-19be nankaro tando ro, kurunna kuli kwasabeye noata kwasa'a gade ro kurun diobe kada litarin kulastinna waltəm sandiya awo gade ro faidatə ro.
In March, the WHO initiated the "SOLIDARITY Trial" in 10 countries, enrolling thousands of people infected with COVID-19 to assess treatment effects of four existing antiviral compounds with the most promise of efficacy.
Kəntagə Marchbe lan, WHOye awo shiro "SOLIDARITY Trial" sayin də badiyono suro lardəwa 10be lan, am duwu kada COVID-19ye sətana gozəna faidawa kurunna kuli kwasabe caman mbeji sowanda nanka ro, wadə faidajinbe zauro kura'a ma.
A dynamic, systematic review was established in April 2020 to track the progress of registered clinical trials for COVID-19 vaccine and therapeutic drug candidates.Vaccine and drug development is a multistep process, typically requiring more than five years to assure safety and efficacy of the new compound.
Kəntagə Aprilbe saa 2020ye lan kulashi mbərshe-aye kuru fasallaye baktəna fuwutə jarabtə litaribe bafro təkkəna am kalimi COVID-19be-a kurunzə-a sandi ro tədinbe kənga ro. Kalimi-a kuru-a tando də duluwu katap kada-a, ngəlama ro saa uwu ma kozəna məradəzəna awo tənandəna bəlin dəye nəlewanzə-a faidatənzə-a tawattəgə ro.
Drug development is the process of bringing a new infectious disease vaccine or therapeutic drug to the market once a lead compound has been identified through the process of drug discovery.
Kurun tando də shima duluwu kalimi au kurun kwasa kam ro faltəyin bəlin ro suluwunabe kasuwu ro kudobe sa awo laa fuwu gərjin duluwu kurun tandobe dən asutiya.
It includes laboratory research on microorganisms and animals, filing for regulatory status, such as via the FDA, for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug.
Suro dən kulashi kəla kuliwa shimbe surimba-a dabbawa-a yen njim ngal dioben dio mbeji, kənda balastəbe au amari matabe mbeji, misal ro FDA futa men, kurun kulashi diobe bəlinye kəla adammana soyen jarabtə baditə nankaro, kuru suro dən katap amari kurun bəlin kasuwu lan faidatəbe au kasuwu ro ikkobe fandoye mbeji.
Development of a COVID-19 vaccine or therapeutic antiviral drug begins with matching a chemical concept to the potential prophylactic mechanism of the future vaccine or antiviral activity in vivo.
Kalimi COVID-19be au kurun kuli yezobe tando də baditin sa bayanna kimiyabe laa-a duluwuwa kalimi dəye kwasa kəriujin au cidawanzə kuli kwasabe gərtəbe-a gəretə lan.
New chemical entities (NCEs, also known as new molecular entities or NMEs) are compounds that emerge from the process of drug discovery to specify a vaccine or antiviral candidate.
Kemikalla bəlin sandiya (NCE au NME) lan notəna sandi ma awowa do duluwu kurun bəlin fodutəye men soluyinma kalimi laa au kurun kuli kwasabe laa'a taganas ro bayanzayin ma.
These have promising activity against a biological target related to COVID-19 disease.
Sandi anyi cida ngəla kəla taranowa awo ro-a kwasa COVID-19be'a leyataye kəlan sadinye wadə mbeji.
At the beginning of vaccine or drug development, little is known about the safety, toxicity, pharmacokinetics, and metabolism of the NCE in humans.
Badiyaram kalimi au kurun tandobe lan, awo gana noata wo k3la Nəlewa-a, asəm-a, futu cidajin-a, kuru NCEwa dəga tiyi adammanabe lan fasaljin-aye kəlan.
It is the function and obligation of drug development to assess all of these parameters prior to human clinical trials to prove safety and efficacy.
Adə shima cida kurun tandobe wo kuru mbu ro walzəna awowa anyi samma so kulastə də kau adammana lan jarabtin də ro, nəlewa-a faidatə-a tawattəgə ro.
A further major objective of drug development is to recommend the dose and schedule for the first use in a human clinical trial ("first-in-human" [FIH] or First Human Dose [FHD], previously also known as "first-in-man" [FIM]).
Məradə kurun tandoe kura gade də shima nəm ngəwu-a loktu-a do kurun də buro salakyen tiyi adammanaben jarabtin də gultə, awo do shiro ("first-in-human" [FIH] au First Human Dose [FHD] gulzayin də, buronna "first-in-man" [FIM]) lan nogatə.
In addition, drug development must establish the physicochemical properties of the NCE: its chemical makeup, stability, and solubility.
Adə ro nzəra lan, kurun tando lan awo shiro "physicochemical properties" sayin NCEwa dəye koktə də mbu: kemikalla tiyi dən dəgana so, faltə baanzə so, kuru yitənzə-a.
Manufacturers must optimize the process they use to make the chemical so they can scale up from a medicinal chemist producing milligrams, to manufacturing on the kilogram and ton scale.
Kurun tandoma so də duluwu faidata kemikal sanandin də ngalwo ro dio də sandi ro mbu ro walzəna, am kurun kemisbe gana gana tando ma lan ciza kamfani kilo-a ton-a satandin ro walza nanka ro.
They further examine the product for suitability to package as capsules, tablets, aerosol, intramuscular injectable, subcutaneous injectable, or intravenous formulations.
Daji awo satandəna də walta napsa futu fato ro sakkiya sandəna də wuzayin, misal ro kapsol, tablet (kwaya), fəttəgəbe, da ro liula lan ikkobe, cidiya katiyibe ro liula lan ikkobe, au tandowa cau ro ikkobe.
Together, these processes are known in preclinical and clinical development as chemistry, manufacturing, and control (CMC).Many aspects of drug development focus on satisfying the regulatory requirements of drug licensing authorities.
Na fal lan, duluwuwa anyi fuwutə ilmu kau-litariye wo-a ilmu litaribe-a lan sandiga kimiyya "chemistry", tando, kuru noto au cistəgə-a lan nogatə.Alamawa au nashawa fuwutə kurunbe ngəwu so hangal məradəwa notobe huwumawa lasis kurunbeye kurnotə ro sadəna.
These generally constitute tests designed to determine the major toxicities of a novel compound prior to first use in humans.
Anyibe suron mbeji ngalla do asəm awowa bəlin buron tiyi adammanabe ro təkkənyi asuta nanka ro tənandəna ma.
The Canadian government announced CA$275 million in funding for 96 research projects on medical countermeasures against COVID-19, including numerous vaccine candidates at Canadian universities, with plans to establish a "vaccine bank" of new vaccines for implementation if another coronavirus outbreak occurs.
Gomnati Canadabeye kunguna "CA$275 million" dola Canadabe miliyon 275 kulashiwa kəla COVID-19 kəriutəe sandi 96 ro cejin sə warmazəna, kalimiwa kada jam'ia Canadaben kunten, kuru fasal au dawari bankə kalimibe koktabe kunten, shi doni waniye waltə koronabairos fəlangjiya faidatin ma.
Clinical trial programs involve three, multiple-year stages toward product approval, and a fourth, post-approval stage for ongoing safety monitoring of the vaccine or drug therapy:
Faraskəramwa jarabtə liaribe də suronzən katapwa yakkə, saa kada'a mbeji awo tənandəna kasada fando ro, kuru katap kən diyeumi, ngawo kasada tuwandənayen, kalimi au kurun ninitəgəbe do letə sədin ma də.
Phase I trials, usually in healthy volunteers, determine safety and dosing.
Katap jarabtəbe kən tilo mi, ngəwu so ro am kəlanzəkko ma nga so lan, nəlewa-a adadu gotinna fodujin.
Phase II trials are used to establish an initial reading of efficacy and further explore safety in small numbers of people having the disease targeted by the NCE.
Katap jarabtəbe kən indi mi də faidatə ruo faidatənzəbe burobe koktə ro tədin kuru nzəliwo suro adadu gana laa am kwasa NCEbe tarajin də tiyinzan mbeji kuru ro
Phase III trials are large, pivotal trials to determine safety and efficacy in sufficiently large numbers of people with the COVID-19 infection.
Jarabtəwa katap kən yakkə me də sandi kura ye, jarabtə toli ma do nzəliwo-a faidatə-a fodujin ma suro adadu am kwasa COVID-19ye sətana ngəwu yen.
If safety and efficacy are adequately proved, clinical testing may stop at this step and the NCE advances to the new drug application (NDA) stage to begin marketing.
Nəlewa/nzəliwo-a faidatə-a kalkal ro kasada sowandəna maa, katap adə lan jarabtə kitaribe mowonzə rotin kuru NCE də katap "new drug application" be ro fuwuzə kojin, kasuwu ro ikko baditə nanka ro.
Phase IV trials are post-approval trials that may be a condition attached by the FDA, also called post-market surveillance studies.
Jarabtəwa katap kən diyeumi də sandima katapwa ngawo kasada tuwandənabe ma do ka'ida FDAye kəlzəgəna ro waljin, shi doni "post-market surveillance studies".
In addition to the tests required to move a novel vaccine or antiviral drug into the clinic for the first time, manufacturers must ensure that any long-term or chronic toxicities are well-defined, including effects on systems not previously monitored (fertility, reproduction, immune system, among others).
Ngalla do kalimi bəlin au kurun kuli kwasabe bəlin litari ro buro salakro ikko ro məradətəna də ro nzəra lan, kurun tandoma so ro mbu ro walzəna nəm asəmma loktu kuruwube au zauro zau ma wo so ngəla ro bayantəna ro, suro dən mbeji ngənəwuwa kəla nzunduwa buron ninitəgənyi soyen ( raktə kənzambibe, kənzambi, nzundu tiyibe kwasa gərtəbe, gabsənanza so'a).
In the United States, this process is called a "new drug application" or NDA.
United States lan, duluwu adə ro "new drug application" au NDA gulzayin.
A clinical trial design in progress may be modified as an "adaptive design" if accumulating data in the trial provide early insights about positive or negative efficacy of the treatment.
Tando jarabtə litaribe dio tədin də mowonzə naptə "adaptve design" au tando gotabe ro ngalwo təyin, sapsawi bayanbe suro jarabtəyen saptə də basira datebe kəla nəm ngəla au nəm diwi kurun dio shima dəye notə cin maa.
The global Solidarity and European Discovery trials of hospitalized people with severe COVID-19 infection apply adaptive design to rapidly alter trial parameters as results from the four experimental therapeutic strategies emerge.
Jarabtəwa dunyabe "Solidarity and European Discovery'ye am litari lan rotəna sandiya kwasa COVID-19be zau dəye sətana ro "adaptive design" faidata lamarra jarabtəbe lezaro, tamoramwa jarabtəwa diyeu dəye luwo sədin lan.
Adaptive designs within ongoing Phase II-III clinical trials on candidate therapeutics may shorten trial durations and use fewer subjects, possibly expediting decisions for early termination or success, and coordinating design changes for a specific trial across its international locations.
Tandowa gotabe au "adaptive design" suro jarabtəwa litaribe katap II - III letə sədin ma kəla kurun kam dondi ro dioben ye də loktu jarabtəye də fulujin kuru am gana faidatin, shawariwa daten rotəbe au kənasarbe lejin, kuru faltə tandowabe fasaljin jarabtə laa taganasbe ro dərinəm kəlle dunyabe lan.
Most novel drug candidates (NCEs) fail during drug development, either because they have unacceptable toxicity or because they simply do not prove efficacy on the targeted disease, as shown in Phase II-III clinical trials.
NCEya ngəwu so loktu fuwutə au ngalwotəgə kurunbe ye lan sakkuruyin, dalil nəm ngəwu asəmzabe yen au təmmaro kwasa shima də ro faidazayimba nanka ro, futu katapwa jarabtəbe kən II - III fəlezana yedei.
The high failure rates associated with pharmaceutical development are referred to as an "attrition rate", requiring decisions during the early stages of drug development to "kill" projects early to avoid costly failures.
Nəm ngəwu ikkurobe ngalwotəgə farmasibe'a leyata də sha "attrition rate" lan bowotin, katapwa kurun tandobe badiyarambe dən shawari cida də yezobe gotə məradəzəna ikkuro zauro kunguna basartə'a ro katə nankaro.
One 2010 study assessed both capitalized and out-of-pocket costs for bringing a single new drug to market as about US$1.8 billion and $870 million, respectively.
Kulashi saa 2010be laaye taman gəna'ata-a liu lan suluyin-a kurun fal long kassuwu ro tulobe ndi so kushezə suruna, kuru alama dola Americabe biliyon 1.8-a kuru dola miliyon 870 kalkal wono.
A median cost estimate of 2015-16 trials for development of 10 anti-cancer drugs was $648 million.
Som taman daube jarabtəwa saa 2015-16 kurun kansabe sandi 10 tandobe də dola miliyon 648.
In a 2016 review of 106 drug candidates assessed through clinical trials, the total capital expenditure for a manufacturer having a drug approved through successful Phase III trials was $2.6 billion (in 2013 dollars), an amount increasing at an annual rate of 8.5%.
Suro nazaru saa 2016 am 106 kurun sandi lan litarin jarabtənabe lan, som darebe kurun tandoma ye cejin ngawo kurun də kasattənayen jarabtə katap kən yakkəme kənasarraye men də shima dola biliyon 2.6 (dola 2013 be lan), adadu do saa wo son ci 8.5% lan tərayin ma.
Seven trials were evaluating repurposed drugs already approved to treat malaria, including four studies on hydroxychloroquine or chloroquine phosphate.
Jarabtəwa sandi tulur kurunna malariabe awo gade ro faidatə ro matin waltana wuzayin, surodən kəra kəla "hydroxychloroquine" au chloroquine "phosphatebe" kəlan tədəna mbeji
Repurposed antiviral drugs make up most of the Chinese research, with 9 Phase III trials on remdesivir across several countries due to report by the end of April.
Kurun kuli kwasabe awo gade ro waltəm faidatə də shima kulashi China be sədin ngəwu so, jarabtə katap III sandi 9 kəla remdesivir ben tədəna dərinəm kəlle lardəwa kadayen, bayanzə datəgəram Aprilbe lan suluyin.
Led by the Bill and Melinda Gates Foundation with partners investing US$125 million and coordinating with the World Health Organization, the COVID-19 Therapeutics Accelerator began in March, facilitating drug development researchers to rapidly identify, assess, develop, and scale up potential treatments.
"Bill and Melinda Gates Foundation" fuwu gǝrjinna ro kuru sawaa mukko kǝltabe kunguna dola miliyon US$125 zar ro dinayin kuru karapka nǝlewbe dunyabe-a fantayin ro, awo shiro "COVID-19 Therapeutics Accelerator" sayin dǝ kǝntagǝ Marchbe lan badiyatǝ, kulashiwu kurun tandobe so'a banazǝgǝ duwaro kurun dio asuza, kulassa, ngalwoza, kuru hapsaa.
The COVID-19 Clinical Research Coalition formed to coordinate and expedite results from international clinical trials on the most promising post-infection treatments.
Ngawana kəla kulashi litaribe COVID-19be kokkatə tamoramwa jarabtəwa dunyabe fasaltə-a kuru letənzə azallata ro dio-a kəla kurun dio zaurofaidajin ro wutin ngawo kamma kwasaye sətana yen.
In early 2020, numerous established antiviral compounds for treating other infections were being repurposed or developed in new clinical research efforts to alleviate the illness of COVID-19.
Badiyaram saa 2020 ben, kurunna kuli kwasabe gərzayin kwasa gade so ro faidazayin kada walta awo bəlin ro faidajin ro tədəna au ngalwotəgəna suro ngənəwuwa kulashi litaribe ye kwasa COVID-19be ba ro dio nanka ro.
For an already-approved drug (such as hydroxychloroquine for malaria), Phase III-IV trials determine in hundreds to thousands of COVID-19-infected people the possible extended use of an already-approved drug for treating COVID-19 infection.
Kurun burotə amari tina au kasattəna (jili hydroxychloroquine kange maleriabe ro sasayin də) ro, jarabtəwa katap kən III-IV dəye səkkə faida kurun caman COVID-19 ro kurun dio ro amari tina ye notin tiyi am COVID-19be sətana duwu kadabe lan.
As of early April 2020, 103 candidate therapeutics were in preclinical or a stage of Phase I-IV development, with trial results for 29 drug candidates expected during April.
Kəntagə Aprilbe saa 2020 ben badiyaramnzən, a, 103 kurun tədin ma sandi kau litari wo lan au katap suro katapwa I-IV ngalwotəgəben, tamoramwa kurun jarabtəbe am 29 suro Aprilben təmatəna'a.
In March, the World Health Organization (WHO) launched the coordinated "Solidarity trial" in 10 countries to rapidly assess in thousands of COVID-19 infected people the potential efficacy of existing antiviral and anti-inflammatory agents not yet evaluated specifically for COVID-19 illness.
Suro kəntagə Marchbe lan, WHOye "Solidarity trial" fasallata ma də citulo suro lardəwa 10ye lan duwa ro tiyi am COVID-19ye sətana duwu kadabe lan faidatə kurunna kuli kwasabe-a kurun futə be-a caman mbejiye kulasnəm notə ro, kurunna anyi COVID-19 ro faidatənzə kuwa yaye kulastənyi.
Do any of the drugs reduce mortality?
Kurunna anyi falnza yaye kərmu fulujin wa?
Do any of the drugs reduce the time a patient is hospitalized?
Kurunna anyiye suro lan falnza yaye loktu kam dondi'a litarin rotin fulujin wa?
Do the treatments affect the need for people with COVID-19-induced pneumonia to be ventilated or maintained in intensive care?
Kurun dio dəye məradəwa am tiyinzan nimoniya COVID-19ye səsangəna injin yintəbeye au na kam zauro dondi ro cistəgəbe ro sandiya ikkobe lezəna wa?
Could such drugs be used to minimize the illness of COVID-19 infection in healthcare staff and people at high risk of developing severe illness?Enrolling people with COVID-19 infection is simplified by using data entries, including informed consent, on a WHO website.
Kurunna jili anyi mowonzə faidatə nəm dondi kwasa COVID-19be dau cidawu nəlewabe-a am zauro suro fujiwo donditəyen kasharu so fulutin wa? Am kwasa COVID-19be'a ikko də sapsawi bayanbe təkkəna faidatəye kəskezəgəna, kasada gullata'an kunten ro, kəla websayit WHObe lan.
After the trial staff determines the drugs available at the hospital, the WHO website randomizes the hospitalized subject to one of the trial drugs or to the hospital standard of care for treating COVID-19.
Ngawo jarabtə yen cidama ye kurunna do litari dən mbeji də nojin, websayit WHObe ye kam litarin rotəna də'a kurunna jarabtə fal də'a kəljin au nəm ngalwo litari dəye COVID-19be kurun dioye.
The trial physician records and submits follow-up information about the subject status and treatment, completing data input via the WHO Solidarity website.
Liyita jarabtəbe dəye bayanna ngawo kəngabe kəla kəndaram kam dəbe-a kurun shiro dio-ayen ruojinye kuru saadinye, sapsawi bayanbe ikko websayit WHO Solidarity men tamojin.
A global safety monitoring board of WHO physicians examine interim results to assist decisions on safety and effectiveness of the trial drugs, and alter the trial design or recommend an effective therapy.
Majilas ninitaabe liyitawa WHObe dunyabe ye tamoramwa loktu ganabe soru bananza nasha shawari kəla nəlewa-a faidatə kurun jarabtəbe dəye-a yen sadin, kuru futu jarabtə tədin də falzayin au shawari kurun dio faidajin gadebe sadin.
A similar web-based study to Solidarity, called "Discovery", was initiated in March across seven countries by INSERM (Paris, France).During March, funding for the Solidarity trial reached US$108 million from 203,000 individuals, organizations and governments, with 45 countries involved in financing or trial management.
Kəra au nazaru adəga samun 'Solidarity'be web furtunzə wo ma, shiro "Discovery" sayin də, kəntagə Marchbe lan dərinəm kəlle lardəwa tulurbe lan INSERM (Paris, France) ye badiyono. Suro kəntagə Marchbe lan, jarabtə "Solidarity"be kunguna tuwandəna də dola miliyon 108 nazəgəna na am so, karapkawa so, kuru gomnatiwa soyen, lardəwa 45 kunguna yezo au jarabtə ro cistaa kəla ro gozana'a
Numerous candidate drugs under study as "supportive" treatments to relieve discomfort during illness, such as NSAIDs or bronchodilators, are not included in the table below.
Kurunna kada kəratə tədin ma naptə kurun dio "banazəyin ma" ye kuttu fantə suro nəm dondiye haptə nanka ro, misal ro NSAIDs so au kurun yintə kəsketəgəbe "bronchodilator" sayin də, sandiya tewur cidiyabe də ro təkkənyi.
Others in early-stage Phase II trials or numerous treatment candidates in Phase I trials, are also excluded.
Gade suro badiyaram katap II jarabtəbe au am sandi ro kurun tədin suro katap I jarabtəbe kadaye suro dən ba.
Drug candidates in Phase I-II trials have a low rate of success (under 12%) to pass through all trial phases to gain eventual approval.
Am sandi lan kurun jarabtin suro katap jarabtəbe I-II'a ye də alama kənasar sadə (cidiya 12% yen) katapwa jarabtəbe samma koza kasada sowandinye də zauro gana.
Hydroxychloroquine is more commonly available than chloroquine in the United States.
"Hydroxychloroquine" də shima fandonzə kəske wo "chloroquine" yaye ro United States lan.
Although several countries use chloroquine or hydroxychloroquine for treatment of persons hospitalized with COVID-19, as of March 2020 the drug has not been formally approved through clinical trials in the United States.
Lardəwa kada "chloroquine au hydroxychloroquine" am COVID-19ye sətana ro sandi lan faidatana kurun sadin yaye, kəntagə Marchbe saa 2020 lan kurun də noata ro kasattənyi jarabtə litaribe men suro United Statesye lan.
Chloroquine has been recommended by Chinese, South Korean and Italian health authorities for the treatment of COVID-19, although these agencies and the US CDC noted contraindications for people with heart disease or diabetes.
Huwumawa Chinabe-a, South Koreabe-a kuru Italybe-a ye shawari "chloroquine" faidatəm COVID-19be kurun diobe sadəna, huwumawa anyi-a US CDC-a ye am kwasa karəgəbe-a shuwurbe-a ro wande faidatanyi sana yaye.
Both drugs have extensive interactions with prescription drugs, affecting the therapeutic dose and disease mitigation.
Kurunna indi so zauro duno'a ro kurunna liyitabe ruozəna am soye caman sasayinna yeltayin, nəm ngəwu kurun dəye ngatə nankaro tayin dəye lejin kuru kwasa dəye kəskezəyin.
Some people have allergic reactions to these drugs.On 12 April, a preliminary clinical trial conducted at a hospital in Brazil was stopped when several people given high doses of chloroquine for COVID-19 infection developed irregular heart rates, causing 11 deaths.
Am laa kurunna sandima də tiyinzaye waano. Kəntagə Aprilbe kaunzə 12nna, jarabtə litaribe badiyarambe litari laa Brazilbe lan tədəna də roatə sa am sandi ro chloroquine kwasa COVID-19be nankaro ngəwu ro sadəna kada baktə karəgəbe kalkal gənyi badiyada, adəye səkkə am 11 baza.
Chinese clinical trials in Wuhan and Shenzhen claimed to show that favipiravir was "clearly effective".
Jarabtəwa litaribe Chinabe Wuhan-a Shenzhen-a lan tədəna dəye fəlezəna kurun "favipiravir" də "zauro faidazəna"wada.
Of 35 patients in Shenzhen tested negative in a median of 4 days, while the length of illness was 11 days in the 45 patients who did not receive it.
Shenzhen lan am 35 sandiya ngaltə tiyinzan ba ro turuna suro kau 4 yen, amma loktu nəm dondi dəye am dondi 45 do sandiro kurun də sadənyi maye də kau 11.
In a study conducted in Wuhan on 240 patients with pneumonia half were given favipiravir and half received umifenovir.
Kulashi Wuhan lan kəla am dondi tiyinzan nimoniya'a sandi 240 yen tədəna, retanza ro "favipiravir" sadə kuru reta də ro "umifenovir" sadə.
The term "preclinical research" is defined by laboratory studies in vitro and in vivo, indicating a beginning stage for development of a vaccine, antiviral or monoclonal antibody therapy, such as experiments to determine effective doses and toxicity, before a candidate compound is advanced for safety and efficacy evaluation in humans.
Jumla "preclinical research" də shima kəra'a lab lan tədin diya lan au tiyi dabba yen ma də wo, adəye fvlejin katap badiyaram kalimi tandobe-a, kurun dio "antiviral or monoclonal antibody"be-a, misal jarabtəwa do nəm ngəwu kurunbe kam ro tin ma-a kuru nəm asəmmanzə-a notə nankaro tədin-a, kau kompawund laa fuwu ro taadə nazaru kvla nəlewa-a faidatənzə-a tiyi adammanben turin ro.
Some antibiotics may be repurposed as COVID-19 treatments:
Kurunna kwasabe laa so də mowonzə sandiya kurun COVID-19be dio ro faidatin.
In March 2020, the main protease of the SARS-CoV-2 virus was identified as a target for post-infection drugs.
Suro kəntagə Marchbe saa 2020e lan, "protease" kura kuli kwasabe SARS-CoV-2be də sha tarano kuruna ngawo kamma kwasabe sətanaye ro asutəna.
This enzyme is essential to the host cell to reproduce the ribonucleic acid of the virus.
Awo shiro "enzyme"sayin adə sel sototəma də ro nasha "ribonucleic acid" kuli kwasabe tandoyen zauro faidajin.
To find the enzyme, scientists used the genome published by Chinese researchers in January 2020 to isolate the main protease.
"Enzyme" də fando nankaro, ilmuwube "genome" doni kuashiwu Chinabe ye kəntagə January saa 2020be lan baksana də faidata "proteasə" də tulo nankaro
As a potential combination therapy, they are used together in two Phase III arms of the 2020 global Solidarity project on COVID-19.
Naptə kurun dio na fal ro kəllatabe dən, sandiya rokko suro mukkowa indi katap kən III me "2020 global Solidarity project on COVID-19" ye lan faida'atə.
A preliminary study in China of combined lopinavir and ritonavir found no effect in people hospitalized for COVID-19.
Kəra badiyarambe China lan tədəna ma lopinavir-a ritonavir-a kəlza am dondi COVID-19ye səta litarin bozana faidazənyi.
b'Drug repositioning (also known as drug repurposing, re-profiling, re-tasking or therapeutic switching) is the repurposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed.
Kurun ba gaden gǝnatǝ (shi doni faida kurunne waltǝm faltǝ, au faidawanzǝ yira lan notǝna dǝ) shima kurun laa kasatkata kwasa gade ro au nǝm dondi laa gade do shi nankaro gǝnyi sha tǝnandǝna ro faidatǝ.
This is one line of scientific research which is currently being pursued to develop safe and effective COVID-19 treatments.
Adǝ lai kulashi ilmube fal do kǝrmaaro tǝgana kurun COVID-19be nǝlewa-aye kuru faidajinye tando nankaro.
Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.SARS-CoV-2 has about 66 druggable proteins, each of which has multiple ligand binding sites.
Diwalla kulashibe gade ye suro lan kalimi COVID-19be tando-a kuru "convalescent plasma transfusion". SARS-CoV-2 protinwanzǝ 66 yedei kurun tǝdin ma mbeji nda so wo so na shiro kǝrtǝyin tiyinzǝn kada mbeji.
Analyzing those binding sites provide the reasonable project of developing effective antiviral drug against COVID-19 proteins.
Na'a kəltabe anyi kulastə də cida ma'ana-a kurun kuli kwasa COVID-19be "protein" wanzəbe ro kurun matabe cin?
Of the most important SARS-CoV-2 target proteins are papain-like protease, RNA dependent RNA polymerase, helicase, S protein, and ADP ribophosphatase.
Protein SARS-CoV-2 be taratin maye suronzan "papain-like protease, RNA dependent RNA polymerase, helicase, S protein, kuru ADP ribophosphatase" mbeji.
Hussein A A, et al studied several candidate compounds which then optimized and analyzed for their skeleton similarity with the highest similar approved drugs in order to accelerate a potent anti-SARS-CoV-2 drug development in his preclinical study to be recommended in a clinical study design.
"Hussein A A, et al" ye "candidate compounds" kada kərazə sandi do kuru kulastə sandiyeyi ba ro tədəna ma kəla nəm samun siffanzabe kurunna kasatkata anti-SARS-CoV-2 be tando ro suro kəra kau litaribe wo ye lan shawari tandonzəye yio.
Chloroquine is an anti-malarial medication that is also used against some auto-immune diseases.
"Chloroquine" də kurun kange maleria be do kwasawa gade soye ro mowonzə faidatin ma.
On 18 March, the WHO announced that chloroquine and the related hydroxychloroquine would be among the four drugs studied as part of the Solidarity clinical trial.
Kəntagə Marchye kaunzə 18nna, WHOye "chloroquine-a hydroxychloroquine-a" də suro kurunna diyeu do kəlanzan kəra au nazaru tədin ma naptə nasha jarabtə litaribe Solidarity nashanzə falbe lan.
New York governor Andrew Cuomo announced that New York State trials of chloroquine and hydroxychloroquine would begin on 24 March.On 28 March, the FDA authorized the use of hydroxychloroquine sulfate and chloroquine phosphate under an Emergency Use Authorization (EUA).
Gomna New Yorkbe Andrew Cuomo ye jarabtəwa chloroquine-a hydroxychloroquine-aye New Yorkbe də kəntagə Marchbe kaunzə 24 baditin sə warmajio. Kəntagə Marchbe kaunzə 28, FDAye amari faidatə "hydroxychloroquine sulfate"be-a "chloroquine phosphate"be-a cina cidiya shara faidatə duwasashibe shiro "Emergency Use Authorization (EUA)" sayin dəyen.
The treatment has not been approved by the FDA's clinical trials process and is authorized under the EUA only as an experimental treatment for emergency use in patients who are hospitalized but are not able to receive treatment in a clinical trial.
Kurun dǝ shima də amari suwandənyi na FDAye duluwuwa jarabtə litaribe yen kuru cidiya EUAye bas lan amari cuwando naptə kurun dio jarabnəm kurube do suro duwasashiben am dondi litarin rotəna ro tədin, sandi do kurun dio jarabtə litaribe sowandanyi.
The CDC has said that "the use, dosing, or duration of hydroxychloroquine for prophylaxis or treatment of SARS-CoV-2 infection" are not yet established.
CDCye wono "faidatə-a, adadu faidatin-a, loktu ndawu ro hydroxychloroquine faidatə" kurun nzətkawo kwasabe ro au kurun COVID-19be dio nankaro də kuwa yaye tawattəgə nyi.
Doctors have said they are using the drug when "there's no other option".
Liyitawa be kurun də faidatayin sa awo diobe gade ba ro waljiya do wono.
A Turkish research team in Istanbul is conducting a small study on the use of chloroquine in combination with zinc, vitamin A, vitamin C and vitamin D.
Kulashiwu Turkeybe Istanbul lan kəra gana laa sadin kəla faida "chloroquine"yen sha "zinc-z, vitamin A-a, vitamin C-a kuru vitamin D-a kəltiya.
Large studies are underway at Duke University and the University of Oxford.
Kəra'a kura kura fuwu lan tədin jami'a Doke be-a Oxford be-a lan.
NYU Langone Medical School is conducting a trial on the safety and efficacy of preventative use of hydroxychloroquine.
Maaraanta ilmu liyitabe NYU Longone Medical School dǝ jarabtǝ kǝla nǝlewa-a faida-a hydroxychloroquine"ye lan sǝdin.
Chinese clinical trials in Wuhan and Shenzhen claimed to show favipiravir was "clearly effective".
Jarabtǝwa litaribe Chinabe Wuhan-a Shenzhen-a lan tǝdǝna ye fǝlezǝna kurun "favipiravir" dǝ zauro faidajin.
35 patients in Shenzhen tested negative in a median of 4 days, while the length of illness was 11 days in the 45 patients who did not receive it.
Am dondi sandi 35 ngalnzaye tiyinzan kuli kwasabe ba fǝlezǝna suro kawu 4ye lan, amma am dondi 45 kurun dǝ sowandanyi dǝ kau 11 ro nǝm dondinza leyono.
In a study conducted in Wuhan on 240 patients with pneumonia, half were given favipiravir and half received umifenovir.
Kǝra laa Wuhan lan kǝla am dondi tiyinzan nimoniya'a 240be lan tǝdǝna dǝn, retanza ro favipiravir cedo kuru reta gabsǝna dǝ ro umifenovir cedo.
The Italian Pharmaceutical Agency reminded the public that the existing evidence in support of the drug is scant and preliminary.
"Italian Pharmaceutical Agency" ye jama meu ro takciyo shada do ngawo kurun dǝye sǝtana dǝ duno ba ye kuru date ye sǝna.
On 2 April, Germany announced that it would purchase the drug from Japan for its stockpile, and use the military to deliver the drug to university hospitals, where the drug will be used to treat COVID-19 patients.
Kǝntagǝ Aprilbe kaunzǝ 2, Germanybe kurun dǝ na Japan yen cuwu gǝnajin sǝ warmazǝna, kuru askǝrra faidatǝ kurun dǝ litariwa jami'a be so ro gǝmzǝyin wono, na kurun dǝ faidatǝ am COVID-19 ye sǝtana ro kurun tǝdin.
According to the South China Morning Post, Shinzo Abe has made overtures to the Trump administration about purchasing the drug.The drug may be less effective in severe cases of illness where the virus has already multiplied.
Gultǝ jerida "South China Morning Post"be lan, Shinzo Abe ye gomnati Trumpbe ro manazǝgǝna kǝla kurun dǝ yioben. Kurun dǝ sa kwasa dǝ zauro zau ro waljiya faidanzǝ kǝske, sa kuli kwasabe dǝ ngǝwujiya.
It may not be safe for use by pregnant women or those trying to conceive.
Kamuwa suro'a au suro gotǝ ro mazayin so dǝ kurun dǝ faidatǝ sandiro illa'a ro waljin.
One study of lopinavir/ritonavir (Kaletra), a combination of the antivirals lopinavir and ritonavir, concluded that "no benefit was observed".
Kǝra laa kǝla lopinavir/ritonavir (Kaletra) shi doni kǝlkǝlno kurunna kuli kwasabe lopinavir-a ritonavir-a yen tǝdǝna dǝye "faida affiye ma turunyi" wono.
The drugs were designed to inhibit HIV from replicating by binding to the protease.
Kurunna dǝ ngǝwutǝ HIVye "protease" dǝ ro kǝrtǝgǝ men daptǝ ro sandiya cetando.
A team of researchers at the University of Colorado are trying to modify the drugs to find a compound that will bind with the protease of SARS-CoV-2.There are criticisms within the scientific community about directing resources to repurposing drugs specifically developed for HIV/AIDS.
Kulashiwu kǝla falla jaami'a Coloradbe kurun dǝ'a saasa awo laa "protease" SARS-CoV-2ye ro kǝrtǝyin fando nankaro. Mana'a bastəbe tuwandəna suro kor ilmuwube lan kəla razuwwa kurunna HIV/AIDS nankaro tənandəna awo gade ro kalaktəgəyen.
The WHO included lopinavir/ritonavir in the international Solidarity trial.
WHOye lopinavir/ritonavir suro jarabtə "Solidarity" dunyabe də ro səkkəna.
Remdesivir was created and developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections . Gilead Sciences subsequently discovered that Remdesivir had antiviral activity in vitro against multiple filo-, pneumo-, paramyxo-, and corona- viruses .
Gilead Sciences"be Remdesvir naptǝ kurun kuli kwasa Ebolabe-a kwasa Marburgbe-a yen sǝtandǝ ngalwo jio. Gilead Sciences"be isə asuwono Remdesivir də cidanzə kuliwa kwasabe gərtəbe mbeji diya lankəla jil kuli kwasabe filo- so, pneumo-so, paramyxo-so, kuru corona- so-a.
One issue with antiviral treatment is the development of resistance through mutations that can lead to more severe disease and transmission.
Lamar fal kurun kuli kwasabe dio'a leyata də shima kurun də'a kuli kwasaye dəye asuzə daji siffa faljin kuru adəye kwasa gade caye maa kozəna-a faltəgə-a suwudin.
Some early pretrial studies suggest remdesivir may have a high genetic barrier to resistance.There are several clinical trials underway, including two conducted by Cleveland University Hospitals; one for people with moderate illness and another for those with more severe illness.
Kəra'a datebe kau jarabtə woye fəlezəna kurun "remdesvir" də kuli kwasabe ye sha duwan səlimba ro. Jarabtəwa litaribe kada fuwun tədin mbeji, suro dən indi litariwa jaami'a Cleveland ye sədəna mbeji; fal am gana dondi ro kuru fal də am zauro dondi ro.
There are three ongoing clinical trials of intravenous vitamin C for people who are hospitalized and severely ill with COVID-19; two placebo controlled (China, Canada) and one with no control (Italy).
Kərmaa ro jarabtəwa 3 diotədin mbeji kəla "vitamin C" cau men am COVID-19be sətana zauro dondi ro ikko ro; indi noto "placebo"be-a (China, Canada) kuru fal də noto ba (Itay).
New York State began trials for the antibiotic azithromycin on 24 March 2020.
Kəriye New Yorkbe ye jarabtəwa kurun kwasa gərtəbe "azithromycin"be də kəntagə Marchbe kaunzə 24 saa 2020be'a badiyino.
Japan's National Center for Global Health and Medicine (NCGM) is planning a clinical trial for Teijin's Alvesco (ciclesonide), an inhaled corticosteroid for asthma, for the treatment of pre-symptomatic patients infected with the novel coronavirus.
National Center for Global Health and Medicine (NCGM) Japanbe ye dawari jarabtə litaribe "Alvesco (ciclesonide)" Teijinbe ye kəlan sədin, kurun asəmabe ci ro futtəgəbe, am dondi koronabairosbe sətana ro nkau alamawa fəlezayin ro kurun dio nanka ro.
A form of angiotensin-converting enzyme 2, a Phase II trial is underway with 200 patients to be recruited from severe, hospitalized cases in Denmark, Germany, and Austria to determine the effectiveness of the treatment.
Jili "angiotensin-converting enzyme 2"be, jarabtə katap II dio baditin am zauro dondi litarin rotəna sandi 200 patients Denmark-a, Germany-a, kuru Austria-lan gotə men, faidatə kurun shima dəye kuru ro.
Researchers from the Montreal Heart Institute in Canada are currently studying the role of colchicine in reducing inflammation and pulmonary complications in patients suffering from mild symptoms of COVID-19.
Lukashiwu "Montreal Heart Institute" Canada lan kəmaa ro katap "colchicine"be futə fulutə-a kazəyiya letə buye-a kurun diobe kəlan kəra sadin suro am alamawa COVID-19be gana gana fəletə badizanaben.
The study, named COLCORONA, is recruiting 6000 adults aged 40 and over who were diagnosed with COVID-19 and experience mild symptoms not requiring hospitalization.
Kəra do shi ro COLCORONA sayin də, rashidiwa 6000 saa 40 samin tiyinzan COVID-19 mbeji kuru alamawa gana gana fanzayin amma litarin rotə məradəzanyi ma gojin.
Women who are pregnant or breastfeeding or who do not have an effective contraceptive method are not eligible.
Kamuwa suro'a au tada ro nganji sadin au duluwunza suro gota baaye ngəla ba'a də mowonzə kəra də ro gotimba.
Several anticoagulants are being tested in Italy.
Italy lan kurunna bu kolzə kərjimba kada jarabtin.
Low-molecular-weight heparin is being widely used to treat patients, prompting the Italian Medicines Agency to publish guidelines on its use.
Heparin kambai ma də shima ngəwu so ro am dondi ro kurun dio ro faidatin, adəye səkkə cidaram kurunbe Italybe shiro "Italian Medicines Agency" sayin dəye kashimowa kəla kurun də faidatəyen cutulo.
A multicenter study on 300 patients researching the use of enoxaparin sodium at prophylaxis and therapeutic dosages was announced in Italy on April 14.
Kəra na'a kadabe kəla am 300yen tədəna do kulashi kəla faidatə "enoxaparin sodium"be naptə kurun kwasabe kamma kənta ro katəbe-a kuru kurun diobe-a adadu gotin ma də warmatəna Italy lan kəntagə Aprilye kaunzə 14.
Since SARS-CoV-2 is a virus, considerable scientific attention has been focused on repurposing approved anti-viral drugs that were developed for prior outbreaks such as MERS, SARS, and West Nile virus.
SARS-CoV-2 dǝ kuli kwasabe daa, hangal nasha ilmube ngǝla ro tina kurunna kuli kwasabe fǝlangtǝwa burobe jili, MERS, SARS, kuru West Nile Virus nanka so ro tǝnandǝna waltem yasa ro.
Ribavirin: ribavirin was recommended for COVID-19 treatment according to Chinese 7th edition guidelines
Ribavirin: ribavirin də kurun COVID-19be shi lan dio ye shawari tina gultə "Chinese 7th edition guidelines" au kashimowa China be baktə kən 7 me.
Umifenovir: umifenovir was recommended for COVID-19 treatment according to Chinese 7th edition guidelines
Umifenovir: umifenovir də kurun COVID-19be shi lan dio ye shawari tina gultə "Chinese 7th edition guidelines" au kashimowa China be baktə kən 7 me.
Some antibiotics that have been identified as potentially repurposable as COVID-19 treatments:
Kurunna kwasa gərtəbe sandiro "antibiotics" gulzayin dəye laanza də mowonzə sandiya kurun COVID-19be dio ro faidatin, sandima:
Tocilizumab (Anti-IL-6 receptor): Approved by China.
Tocilizumab (Anti-IL-6 receptor): China ye kasatsəna au amari cina.
Also trials in Italy and China. and see Tocilizumab#COVID-19.
Adəgaima jarabtəwa Italy-a China-a lan. kuru wune Tocilizumab#COVID-19
It is unclear yet whether conditions arising during pregnancy including diabetes, cardiac failure, hypercoagulability or hypertension might represent additional risk factors for pregnant people as they do for nonpregnant people.From the limited data available, vertical transmission during the third trimester probably does not occur, or only occurs very rarely.
Lamarra nəlewabe sa kamu surowa maa cizayin jili kwasa shuwur so, karəgə ngəla ro cidajimba so, tuttə zawal bu ye na'a kozəna au kəmba bu ye so dəye fujiwo gade kamuwa surowa ro suwudin la suwudimba futu am ngai ro suwudin də ro də kuwa yaye asutənyi. Sapsawi bayanbe gana mbeji dən, faltəgə daatala suro kəntagə yakkə darebe dən wakajimba wo, au duwan wakajimba wo.
There is no data yet on early pregnancy.
Sapsawi bayanbe kəla badiyaram suro be lan ba.
Little evidence exists to permit any solid conclusions about the nature of COVID-19 infection in pregnancy.
Shada gana dəga shi doni kolzə jili kwasa COVID-19be loktu kamu surowa be ye kəlan awo fal kət gultin ma də.
A case series of 43 women from New York who tested positive for COVID-19 showed similar patterns to non-pregnant adults: 86% had mild disease, 9.3% had severe disease and 4.7% developed critical disease.
New York lan kessa au lamarra zatata kamuwa 43be samma COVID-19 tiyinzan mbeji də jili kwasanzabe də ammurawa suro ba'a ye'a samun: suronzan ci 86% də gana kwasa də mbeji, ci 9.3% də zauro kwasa də mbeji, kuru ci 4.7% də taidazə kwasanza zau ro walzəna.
Fetal distress was reported in two.
Tada surobe kəndanzə kuttuye bayan indi tuwandəna.
None of the women developed severe COVID-19 pneumonia or died.
Suro kamuwa dəyen fal ma nimoniya COVID-19be sandiya sətana au bazəna ba.
All of them had live birth pregnancies and no severe neonatal asphyxia was observed.
Sandi samma futu noata men isa ceshombo kuru mutə ngawo kənzambiye zauro zau turunyi.
The samples of breast milk, amniotic fluid, cord blood and neonatal throat swab were tested for SARS-CoV-2, and all results were negative.In another study on 15 pregnant women, majority of the patients presented with fever and cough, while laboratory tests yielded lymphocytopenia in 12 patients.
Samfərwa cam nganjibe-a, nji tadarambe-a, bu kənzabe-a kuru samfvr nguwaltobe tini ngawo kənzambiyen gotəna dəye SARS-CoV-2 ro ngaltəna kuru tamoramwa samma soye ba fəlezəna. Kəra laa gade kəla kamuwa surowa sandi 15yen tədəna lan, ngəwunza so kange-a kasau-a sandiya sətana, kuru ngalla labye "lymphocytopenia" tiyi sandi 12 yen fəlewono.
Computed tomography findings of these patients were consistent with previous reports of non-pregnant patients, consisting of ground-glass opacities at early stage.
Awowa foto nasha nasha be kompiutabe am dondi anyi be lan tuwandəna am dondi suro baa ye burobe'a kalkalzəna, sandi doni suronzan badiyaram lan kalwa yedei turin.
Follow-up images after delivery showed no progression of pneumonia.Media reports indicate that over 100 women with COVID-19 might have delivered, and in March 2020, no maternal deaths were reported.
Fotowa ngawo kənzambiyen gotəna ye nimoniya ba fəlezəna. Bayanna fatowa hawarbe soye fəlezana kamuwa 100 samin tiyinzan COVID-19'a sasambəna, kuru suro kəntagə March saa 2020be lan, kərmu kənzambi'a leyata fal ma tuwandənyi.
Their guidelines thus advise that any pregnant person admitted to hospital with a COVID-19 infection should receive at least 10 days of prophylactic low-molecular-weight heparin after being discharged from the hospital.
Kashimowanza dəye shawari cina kam surowa jiliwi yaye litarin sha rozana tiyinzən kwasa COVID-19be'a də gananzə yaye kau 10 ro kurun shiro "prophylactic low-molecular-weight heparin" gulzayin də gozə, ngawo litarin salamzana yen.
There are no data yet concerning the implications of COVID-19 infections for labour.
Sapsawi bayanbe ba kəla kazəyiwa kwasa COVID-19be sa nzaruwu wakajiya suwudin yen ba.
One infant girl born to a mother with COVID-19 had elevated IgM levels two hours after birth, suggesting that she had been infected in utero and supporting the possibility of vertical transmission in some cases.
Fero kəli kamu COVID-19-a ye sambəna laa də tiyinzən IgM ngəwu wo no ngawo awa indi yen, adəye fəlejin kwasa dəye suro tadaramben sha cita kuru mowontə faltəgə daatalabe ye ngawo sətayin lamarra laan.
A small study involving 6 confirmed COVID-19 mothers showed no indication of SARS-COV-19 in their newborns' throats or serum but antibodies were present in neonatal blood sera samples, including IgM in two of the infants.
Kəra gana laa kamuwa tada kəli tiyinzan COVID-19-a ro tawattəgəna sandi 6'a tədəna də ye alama SARS-CoV-2 ye suro nguwalto au bu nduli kəli dəyen fəlezənyi amma awowa kwasa gərtəbe suro samfər bu ngawo kənzambi ye dən mbeji, IgM suro nduli kəli indi yen kunten.
This is not usually passed from mother to fetus so further research is required to know whether the virus crossed the placenta or whether placentas of women in the study were damaged or abnormal.
Adə ya lan ci zə tada ro kojimba wo ngai dən, adəye səkkə kulashi gade məradətəna kuli kwasabe də kənza də farzə wa kowono au kənza kamuwa dəye də batti au kalkal gənyi ro notə nanka ro